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Picture 1: Participants to the 2015 ECIBC Plenary.
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The second plenary of the European Commission Initiative on Breast Cancer 
(ECIBC) took place from the 9 to the 11 December 2015 in Baveno, Italy. The 
purpose of the ECIBC Plenaries is to inform stakeholders on the activities of 
the ECIBC while at the same time seeking their feedback. The ECIBC was en-
dorsed by members of the European Parliament during the Plenary through video 
messages by Anneli Jäätteenmäki, Vice-President European Parliament, and Alojz 
Peterle, President of the Member of Parliament’s (MEP) Against Cancer.
The 2015 edition of the Plenary, entitled ‘Improving breast cancer screening, diag-
nosis and care in Europe’, included updates on the ECIBC, highly relevant key-
note speeches, and presentations both on related projects and on the situation of 
breast cancer services in different countries.
In addition it focused, via dedicated parallel sessions, on four topics relevant for 
the ECIBC that, even if they have been debated for some years, are at present still 
largely under discussion:
• continuity of care;
• communication (and its assessment) in person-centred services;
• key outcomes for studies on breast cancer screening;
• volume-outcomes relation in breast cancer care.
Participation to the conference was only upon invitation. Ninety-seven persons 
from outside the JRC participated in this meeting, representing policy makers, pa-
tients, stakeholders, as well as representatives from other European Commission 
Directorates-General.
While the JRC staff provided and overview of the ECIBC progress, chairs of the 
two working groups, the Guidelines Development Group (GDG) and Quality As-
surance Scheme Development Group (QASDG) presented interim outputs and 
plans of the two ECIBC pillars.
Abstract
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During the Event, the dates for 2016 Plenary were announced and the ECIBC web 
hub was launched. The web hub will constitute the interface of the project with 
all stakeholders, including citizens, enabling them to find useful information on 
the progress of the project in the development phase and, in future, the guidelines 
and requirements defining the quality benchmark to be achieved by breast cancer 
services throughout Europe.
Overall, participants judged the 2015 Plenary as meeting their expectations con-
cerning the content and organisation of the event and provided valuable sugges-
tions for aspects that may still be improved. In summary, the 2015 ECIBC Plenary 
succeeded both in informing stakeholders, while seeking their feedback and en-
dorsement, and in further shaping the ECIBC pillars.
The ECIBC will continue to provide a platform for networking at the interface 
between research and policy. The ECIBC Plenaries aim at promoting a factual 
dialogue between science, clinicians, policy makers and administration, and, last 
but not least, patients in order to improve care for women confronted with breast 
cancer.
1. Introduction | 9
The ECIBC Plenaries are set up to inform Member States and accessing countries, 
patients and other stakeholders, policy makers and the scientific and health-policy 
community about the aims, activities, and achievements of the ECIBC, while at 
the same time seeking their feedback and input. Furthermore, the Plenaries also 
aim to get policy makers and stakeholders, active in breast cancer care, linked and 
engaged with the ECIBC initiatives. The 2015 edition, focused on topics under the 
limelight in healthcare research, was structured in three parts:
1. Current state of ECIBC-projects. This included the JRC reporting on:
• the voluntary European Quality Assurance Scheme for Breast Cancer Services 
(the European QA scheme)
• the European guidelines for breast cancer screening and diagnosis (the Euro-
pean Breast Guidelines)
• the platform of guidelines for all breast cancer processes (the Platform)
• the web hub to host all ECIBC deliverables (launched during the first day of 
the Plenary)
• surveys and research activities carried out at JRC to support the ECIBC 
(organisation of breast cancer services in Europe, conformity assessment 
for breast cancer services in Europe, a review of existing quality assurance 
schemes and other ongoing research).
2. Current key topics in breast cancer care research. This part of the meeting in-
cluded presentations on:
• The Concept of patient centred care in measuring the quality of health services
• Dealing with evidence from qualitative research in guideline development
• Clinical practice guidelines: International consensus on methodological standards
• Other Projects on Cancer from EU-countries and abroad, covering CanCon, 
EU-TOPIA, US-Breast Centre Accreditation, and the European Network of 
Cancer Registries.
1. Introduction
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Additionally, parallel workshops were organised in order to address the following 
topics: 1. Continuity of care, 2. Communication in person-centred services, 3. Key 
outcomes for studies on breast cancer screening, and 4. Volume-outcome relation 
in breast cancer care.
3. The needs for ECIBC implementation covering:
• Country profiles on breast cancer care (posters and oral presentations)
• Equity of access to breast cancer screening programmes
• Experiences from patient advocacy
• Posters with National Accreditation Bodies activities in the field of breast 
cancer care
During the final wrap-up session, in addition to drawing conclusions on how the 
topics discussed could impact on the ECIBC, the dates of the 2016 edition of the 
ECIBC Plenary were announced (24th and 25 th November 2016).
2. Organisation and participants | 11
The second plenary of the ECIBC took place from the 9 December until 11th 
December 2015. Meeting venue was the Grand Hotel Dino in Baveno, Piedmont, 
Italy.
Participation to the conference was only upon invitation. As from 20th August 
2015, the Plenary dates were announced to invitees via email and with a short 
description of the event’s scope. The official invitations to participants were sent 
out on 5 th November 2015 and the registration was open between 19th and 30th No-
vember 2015.
Members of the European Parliament, all ECIBC National Contacts, represent-
atives of National Accreditation Bodies of European countries, the members of 
the two ECIBC working groups, Guideline Development Group (GDG) and the 
Quality Assurance Scheme Development Group (QASDG), cooperation partners 
of the ECIBC, representatives of European associations dealing with breast can-
cer screening, diagnosis and treatment, representatives of patient organisations, 
researchers and clinicians were invited.
97 persons from outside the JRC participated in the meeting, of whom 22 gave a 
presentation during either the plenary session or one of the parallel workshops.
The agenda and Plenary concept was made available via e-mail to all persons 
invited. After the event, and upon written consent, presentations and the list of 
participants were posted on the ECIBC web hub.
Each session was moderated by the host, the JRC. Most of the sessions were 
held as plenaries, apart from four parallel workshops that were offered during the 
second day. Each of these parallel workshops was chaired by experts in the field 
together with a representative of the JRC Healthcare Quality Team. Rapporteurs 
reported on progress and outcomes of workshops during the third day. Key note 
speeches were held during the morning of the second and third day.
2. Organisation and participants
12 | The European Commission Initiative on Breast Cancer (ECIBC): Plenary 2015
Annex 1 contains the biographies of speakers and Annex 2 the list of the final 97 
participants from outside the JRC.
All presentations are available at the link ECIBC web hub–Plenary 2015 page,1 
were a Flash Report of the Plenary 2015 is also available.
1. http://ecibc.jrc.ec.europa.eu/-/plenary-of-the-european-commission-initiative-on-breast-cancer-ecibc-improving-breast- 
cancer-screening-diagnosis-and-care-in-europe-.
3. Agenda and presentations | 13
Each of the three days was characterised by an ECIBC-related thematic focus:
• The first day included welcome notes and reports on the current activities and 
projects of ECIBC.
• The second day comprised reports on national, European, and international 
activities and projects related and relevant to the ECIBC. The afternoon was 
dedicated to parallel workshops. 
• During the third day, results from the parallel workshops were presented, 
last-minute presentations were held and an outlook on the event and on the 
ECIBC concluded the Plenary.
The final agenda (found in Annex 2) and presentations were as follows (see also the 
details available on the ECIBC web hub: ECIBC web hub–Plenary 2015 page 2):
3.1. Day 1: ECIBC current state
3.1.1. Welcome & Opening
Video message: (Anneli Jäätteenmäki, Vice-President European Parliament) https: 
//www.youtube.com/watch?v=3LIlRFWxAsE.
Video message: (Alojz Peterle, President of the MEPs Against Cancer, European 
Parliament) https://www.youtube.com/watch?v=W6UCgYyCyZk.
Welcome note (Krzysztof Maruszewski, JRC).
• EC policies on (breast) cancer (Michael Hübel, DG SANTE)
 The European Union has been active on cancer prevention and control since 
1985. Cancer screening is a cornerstone of this approach. In the 2003 Coun-
2. http://ecibc.jrc.ec.europa.eu/-/plenary-of-the-european-commission-initiative-on-breast-cancer-ecibc-improving-breast- 
cancer-screening-diagnosis-and-care-in-europe-.
3. Agenda and presentations
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cil recommendations on cancer screening, the Council set out principles of 
best practice in the early detection of cancer, and invited all Member States to 
take common action to implement national population-based screening pro-
grammes for breast, cervical and colorectal cancer, with appropriate quality 
assurance. European Guidelines for quality assurance for breast, cervical and 
colorectal cancer screening have been developed as benchmarks on how to 
go about screening. Based on this work, DG Health and Food Safety have 
requested the Commission’s Joint Research Centre to develop a new version 
of the European Guidelines for Quality Assurance in Breast Cancer Screening 
and Diagnosis, and a voluntary European Quality Assurance scheme for Breast 
Cancer Services underpinned by accreditation and evidence-based guidelines–
the European Commission Initiative on Breast Cancer.
• Patients’ expectations on EC-(breast) cancer policies (Susan Knox, Europa Donna)
 EU policy provides the framework for improving and defining standards for 
breast cancer services in the EU and beyond. The EC ‘European Guidelines 
for quality assurance in breast cancer screening and diagnosis’ published in 
2006 provided the basis for Europa Donna to advocate for the key priorities of 
screening and treatment in specialist breast units. Our short guide based on this 
document was translated into 17 languages and countries outside the EU are 
using it as well. ED has also worked on getting important Resolutions and Dec-
larations on breast cancer passed by the European Parliament. For the last 10 
years we have worked with the Commission on disseminating information and 
providing training concerning EU guidelines to member countries. This has led 
to the development of the ECIBC for which we have the highest expectations; 
Europa Donna views this as the culmination of our advocacy work for the last 
seven years.
Current state of the ECIBC project
• ECIBC overview (Donata Lerda, JRC)
 The European Commission (EC) launched the European Commission Initia-
tive on Breast Cancer (ECIBC). It is a project to support European countries 
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with a harmonised and benchmarked policy for improving breast cancer care 
quality while reducing inequalities. Over the past 20 years, many guidelines 
have been made available at national/regional/local level, and quality assur-
ance (QA) schemes have been developed and are running across EU. However, 
an evidence-based approach was not always applied and the auditing systems 
are diverse. The JRC, coordinator of ECIBC upon DG SANTE’s mandate, 
with the invaluable collaboration of ECIBC National Contacts, patients’ asso-
ciations and experts, has mapped out how breast cancer services are organised 
in Europe, what ISO standards are applied in breast cancer care, what is the 
availability of breast cancer data, and what breast cancer QA schemes are pres-
ent. The next steps are (i) to develop evidence-based guidelines, (ii) to set-up a 
modular, flexible and voluntary QA scheme underpinned by that evidence and 
by Regulation (EC) No 765/2008 on accreditation, including training require-
ments and a dedicated website.
• Development of a voluntary European Quality Assurance Scheme for Breast Cancer 
Services (Francesco Sardanelli, ECIBC-QASDG vice chair)
 The Quality assurance team developing the European QA scheme consists of 
the ECIBC coordination team, the secretariat, the QASDG, contributing 
non-QASDG members, such as the European Cooperation for Accreditation, 
scientific advisors, and external experts.
 The QASDG is presided by a chair and a vice chair, managed by a steering 
group and structured according to sub-groups dealing with the following sub-
jects: Testing, Glossary, Organisation, Indicators and Certification.
 The QASDG working modalities are based on agreed rules of procedure that 
have already been approved. They foresee that
° the European QA scheme is built on the basis of best available evidence and 
best professional practice, taking into account the legal and policy context,
° evidence is gathered from the European Guidelines for Breast Cancer Screen-
ing and Diagnosis and the Platform of guidelines for processes of care other 
than screening and diagnosis,
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° requirements will be established using the methodology of Delphi rounds, 
including, apart from the requirements stemming from the guidelines, also 
existing requirements obtained via calls,
° both the scope of the scheme (at the initial stage) and the final scheme, in-
cluding specific requirements will be enhanced by a call for feedback,
° the scheme will be piloted before implementation.
 The frame of the European QA scheme will be shaped by (a) the requirements 
applied by the national accreditation bodies to accredit the certification bodies 
that want to assess the quality of care of clinical processes and (b) the specific 
requirements for breast cancer services to attain the certification. In addition, 
national accreditation bodies will accredit laboratory and testing.
 The next step is a public call for feedback on the European QA scheme scope, to 
be launched by February 2016.
• Development of European guidelines for breast cancer screening and diagnosis (Chris de 
Wolf, ECIBC-GDG co-chair)
 The guideline development team consists of the ECIBC coordination team, 
the secretariat, the GDG, and contributing non-GDG members, such as the 
systematic review team, represented by the Iberoamerican Cochrane Centre, 
scientific advisors, and external experts. 
 The GDG is presided by both a chair and a vice chair responsible for the content 
and a chair and a vice chair responsible for ensuring a rigorous methodological 
approach. It is managed by a steering group and structured according to task 
forces dealing with the following subjects: Glossary, Guideline development 
methods, Citizens’ and stakeholders’ involvement, and Dissemination evalua-
tion and chapters’ subgroups (Screening, Diagnosis, Communication, Training, 
Interventions to reduce Inequalities, Monitoring and evaluation of screening 
and diagnosis).
 The GDG working modalities are based on agreed rules of procedure that are 
being approved. It is also foreseen that:
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° guideline recommendations will be selected following the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE) approach,
° the group will be working in onsite meetings as well as by online cooperation 
using the Communication and Information Resource Centre for Administra-
tions, Businesses and Citizens (CIRCABC) and the GRADE’s software for 
Guidelines Development (GDT),
° the guidelines will be enhanced by calls for feedback both on their scope (at 
the initial stage) and on the final version.
 Currently the GDG is collecting PICO questions to build the evidence basis 
for the guideline. The next step is a public call for feedback on the European 
Breast Guidelines’ scope, to be launched by January 2016.
• Guidelines platform and web hub (Liisa Pylkkanen, JRC; Luciana Neamtiu, JRC)
 While the ECIBC will use the future European Guidelines for Breast Cancer Screen-
ing and Diagnosis as the baseline for developing the European QA scheme for 
the screening and diagnosis processes, evidence for other care processes will 
come from national and international guidelines developed by other entities. 
Therefore, high-quality evidence-based guidelines will be collected in a Guide-
lines Platform. The goal of this platform is to provide healthcare providers 
and citizens with clear and objective guidance on all breast cancer services and 
promote informed decisions. The process to search, evaluate, update, and host 
these guidelines will be located in the ECIBC web hub. The web hub will be 
the interface of the ECIBC with the public.
• Surveys and research activities: breast cancer screening and care in Europe, implemented 
breast cancer quality assurance schemes, and standards used in breast cancer care (Silvia 
Deandrea, JRC; Aslı Ulutürk, JRC)
 Developing a single European quality assurance scheme and guidelines appli-
cable in all Member States, as foreseen by the ECIBC, is highly complex. In 
order to encompass different healthcare systems’ settings and the related qual-
ity systems within each country, a series of research activities was carried-out 
covering Member States and associated countries. A first survey in 2012-2013 
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evaluated the structures of breast cancer services (http://ecibc.jrc.ec.europa.
eu/-/report-lbna26591); a second survey in 2013-2014 assessed the use of ISO 
accreditation, certification and conformity assessment for breast cancer services 
under National Accreditation Bodies’ governance (http://ecibc.jrc.ec.europa.
eu/-/report-lbna27382); and a study reviewed existing quality assurance pro-
grams and healthcare accreditation of breast cancer services (http://ecibc.jrc.
ec.europa.eu/-/report-lbna27382enn). Furthermore, a study, co-authored with 
the Fundación para el Fomento de la Investigación Sanitaria y Biomédica de 
la Comunitat Valenciana (FISABIO), collected data for breast cancer screen-
ing programmes general indicators and explored the equity of access to those 
programmes; related papers are being submitted for publication. Finally, data 
collected from a survey, co-organised with Europa Donna and Fatima Cardoso, 
are currently under evaluation: the survey looked at the implementation of the 
European Parliament Resolution on breast units. Information from all these 
research activities provides a comprehensive overview on the reality of breast 
cancer care in Europe and important background information for the develop-
ment of the ECIBC objectives.
3.2. Day 2: Current topics in breast cancer care research
3.2.1. Keynote
• The Concept of patient centred care and measuring the quality of health services (Chris 
Graham, Picker Institute)
 Over the last two decades, the concept of person (or patient) centred care has 
become increasingly prominent in health services across the world. The aim 
of person centred care is to provide health services in a way that respects and 
responds to the knowledge, preferences, needs, and values of individual service 
users. At the core of the approach is the principle that users of health services 
should have a role in assessing the quality of care, by being given the oppor-
tunity to provide feedback about their own experiences. Measures of ‘patient 
experience’, including but not limited to patient surveys, are now widely used 
to assess the extent to which care is person-centred. This talk will trace the de-
velopment of person-centred care and, alongside it, the increasing importance 
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Picture 2: Audience to the ‘Current state of the ECIBC project’ session.
 
 
of measuring and using patient experience. This will address the role of patient 
feedback in measuring and understanding service quality, with examples from 
cancer care and chronic disease settings.
3.2.2. Practice and challenges in assuring the quality 
of breast cancer care in Europe
The current status of breast cancer care was presented for Hungary (by Kitti Hor-
váth, Chief Medical Officer’s Office, Hungary), Malta (by Miriam Dalmas, Minis-
try for Energy and Health, Malta) and Norway (Solveig Hofvind, Cancer Registry 
of Norway). These countries do not only differ in their structural preconditions, 
with Hungary being a new Member State of 10 million inhabitants, Malta, a rather 
small state with about half a million inhabitants, and Norway a wealthy EFTA 
country, but also with regards to their organisation of breast cancer screening, care 
and quality assurance.
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Breast cancer care and implemented quality assurance–A report on Hungary
Hungary is a middle-income Central-Eastern European country, which joined the 
EU in 2004. It currently has 9.87 million inhabitants. The cancer burden is rather 
heavy. Overall cancer mortality rate in 2013 was the highest among the EU28. 
Regarding breast cancer incidence, 34.7/100.00 new cases and 25.0/100.000 fatal 
cases were reported.
The Chief Medical Officers’ Office, on behalf of the National Public Health and 
Medical Officers Services (ÁNTSZ) carries the task for organisation, coordination, 
monitoring and evaluation of breast cancer screening. For overall cancer care the 
National Cancer Institute bears the professional responsibility. Population-based 
organised breast screening facilities in Hungary are available since 2002; 42 Breast 
Screening Centres have been contracted by tender. Each centre has been connected 
with other elements of breast cancer care, forming a Breast Unit, as defined by the 
European Guidelines 4th edition (2006).
The National Screening Registry regularly receives feedback from the mammog-
raphy units about all indicators. With appropriate interpretation of these data, 
quality assurance for breast cancer screening can be guaranteed.
Breast cancer care services in Malta
Aim: Patients diagnosed with breast cancer in Malta are navigated through sev-
eral different cancer care services. These services are provided at different health-
care facilities and by different groups of professionals. This presentation will illus-
trate the breast cancer care services in Malta.
Background: The Republic of Malta consists of three main islands, Malta, Gozo 
and Comino, forming an archipelago in the Mediterranean Sea that has the high-
est population density in Europe combined with the lowest total population of 
any European Union (EU) Member State. In 2011, life expectancy at birth was 78.4 
years for men (compared with 77.4 years for the EU as a whole) and 82.6 years for 
women (compared with 83.2 for the EU).
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In 2013, there were 1687 new cancers registered in Malta. Of these, 309 were pri-
mary cancers of the female breast. There were 848 deaths attributed to cancer. 
These included 83 deaths attributed breast cancer. The 5-year relative survival from 
female breast cancer published in EUROCARE-5 stood at 81%.
Breast cancer care services: National population-based breast screening was in-
troduced in 2009. Women aged 50-65 years are being invited for a mammographic 
screening every three years. A Breast Clinic at the main general hospital (Ma-
ter Dei Hospital–MDH) has been in operation since 2000. The clinic is led by 
two breast surgeons. These surgeons manage the vast majority of breast cancer 
cases diagnosed and treated in Malta. A multi-disciplinary team (MDT) meet-
ing takes place every Thursday and during this meeting new cases referred by 
the screening programme or arising through the symptomatic route are discussed 
and a cancer care pathway is mapped for each patient. Individual patients may 
be re-discussed in more than one MDT session. In most cases, the imaging and 
pathological examinations and all surgical procedures are carried out at MDH. 
Oncology treatment (including all radiotherapy) is given at the Oncology Centre. 
A new Oncology Centre on MDH grounds was opened in the summer of 2015. 
A specialized palliative care unit operates from the Oncology Centre. Palliative 
care in the community is coordinated and provided by Hospice Malta which is a 
non-governmental organisation.
In Malta, comprehensive breast cancer care is offered in cancer centres. These 
centres have not been yet made subject to any specific legal or regulatory require-
ments or been included in a national or international accreditation or certifica-
tion system. However, there is work in progress to introduce a system of quality 
assurance.
Norway
Norway has a long standing, well established and refined system of public health 
registries. Data from different registries can be linked by personal identifiers. Thus 
comprehensive person-related routine data are available and can be used to evalu-
ate and quality assure breast cancer screening, diagnosis and treatment.
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3.2.3. Together for improving care for (breast) cancer: 
other projects on cancer from EU and abroad
• CANCON (Tit Albrecht, National Institute of Public Health, Slovenia)
 The Joint Action CANCON (Cancer Control) is focusing on the quality im-
provement in four important areas of cancer control: (i) development of com-
prehensive cancer care networks, (ii) community cancer care, (iii) survivorship 
issues, and (iv) guidance on several existing or potential screening programmes. 
In the latter, several challenges and new knowledge have shed new light on 
how screening programs should be organised. A work package on screening is 
exploring guidance on cervical, breast, colorectal, prostate, lung and stomach 
cancer. This should provide an up-to-date knowledge and advice to policymakers 
on how to act in the face of the challenges arising from these screening pro-
grammes. The listed core topics will each prepare a comprehensive chapter for 
the publication entitled European Guide for Quality Improvement in Cancer 
Control, which will be published at the end of the project and presented at the 
final conference, which will be one of the events of the Maltese Presidency to 
the Council of the European Union.
• EU-TOPIA: Towards improved screening for breast, cervical and colorectal cancer in all 
of Europe (Harry de Koning, Erasmus University)
 Breast, colorectal and cervical cancer cause 250000 deaths each year, represent-
ing 20% of EU-cancer mortality. Although important progress has been made 
in both detection and treatment, there is persisting inequity in progress to re-
duce its burden. The objective of EU-TOPIA is to systematically evaluate and 
quantify the harms and benefits of the running programs for breast, cervical, 
and colorectal cancer in all European countries, and identify ways to improve 
health outcomes and equity for citizens. We will first identify significant in-
equities in screening outcomes by assessing the key set of quality indicators 
for benefits and harms in each country. Using these indicators, outcomes and 
cost-effectiveness of existing cancer screening programs in 2015 will be estimated. 
For this, state-of-the-art models of the natural history of the cancers will be 
constructed, using country-specific data. Barriers hindering implementation of 
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optimal screening programs will be assessed, leading to road maps for improved 
screening. These road maps contain feasible changes, e.g., to extend or reduce 
the program, to change the screen test used or change key quality indicators, to 
perform activities that reduce screening related harm or incorporate new devel-
opments in screening, and provide policymakers with evidence for increased, 
decreased or optimized use of screening. The project will lead to reduced ineq-
uity, reduced number of cancer deaths and over-diagnosed cases, and increase 
in life years gained and better cost-effectiveness by 2025.
• Breast Center Quality Assessment Programs in US (Cary Kaufmann, FACS)
 Breast Care provided by the multidisciplinary team makes it difficult to corre-
late results, whether good or bad, with interventions. In addition, there are rel-
atively few evidence based quality metrics available to apply to centres wishing 
certification. Appropriate quality measures are those which are a) recognized by 
providers as being important, b) have variation in performance across centres, 
c) are feasible to extract performance data, and d) have a positive cost-benefit 
ratio. Another confounding problem is that quality measures must apply to 
the many varieties of breast centres, large and small, academic and community, 
urban and rural.
 In the US, two programs developed independently, each providing half of the 
quality equation. One program (NAPBC) focused on defining the structural 
components of care. They had to define structural requirements that were rigid 
enough to maintain high quality care but flexible enough to recognize the real-
ities of the local community. The second quality program (NQMBC) focused 
on process measurements, or how well does the multidisciplinary team perform 
in each area of breast care. Although they measured specific performance lev-
els, they had difficulty identifying benchmarks. Providing a single benchmark 
may be too high for many centres, while appearing too low and not providing 
improvement incentive for the better quality centres. The ideal breast centre 
certification combines both multidisciplinary structural requirements along 
with process of care assessment (including benchmarks) that recognize both the 
realities of local environment and the needs of individual patients.
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• European Network of Cancer Registries (Nadya Dimitrova, Bulgarian National 
Cancer Registry)
 There are over 20 national and 82 regional cancer registries in Europe, covering 
72% of the population of the EU. All of these registries have contributed, or 
have the potential to contribute, to the quality of breast cancer care in some 
way. Because definitions are standardized across Europe, registries can provide 
long-term descriptions of trends in breast cancer incidence, stage, treatment, sur-
vival and mortality by country, region or hospital. Registries linked to screening 
programme data can also identify and compare in detail (including molecular 
makers) symptomatic, screened and interval cancers, and allow international 
comparisons. Improving data collection through the establishment of links to 
clinical cancer registries and the wider availability of electronic data means reg-
istries have an increasing scope and timeliness of data which can be linked to 
measures of quality of care and screening history. They can also help estimate 
the cost-effectiveness of new technologies, and of interventions such as rapid 
referral clinics or specialist breast centres. The potential of cancer registries to 
contribute to breast cancer quality assessment is limited by a number of factors. 
Cancer registration in Europe remains heterogeneous for historical, economic 
and legal reasons, so the scope of data captured by registries is very variable. 
Some countries have complete population coverage, others have regional cov-
erage, and a few have no effective population-based cancer registration. Some 
registries do not have access to death certificates, which makes survival calcu-
lation inaccurate. Many capture stage and treatment at diagnosis, but not all. 
Some can provide more detail, for instance on type of surgery, completeness of 
excision, molecular markers, comorbidity and follow-up data, and a few collect 
data on quality of life, for selected cohorts. Linkage of screening data to cancer 
registries is not being done in some countries for cost, legal or administrative 
reasons.
 The ENCR, with JRC, is working on improving the standardization and cover-
age of cancer registration in Europe. There is considerable potential for quality 
assurance and research through more widespread sharing of the more exten-
sive data now collected by registries, clinical programmes and screening pro-
grammes, and the more detailed analysis of the data already collected.
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3.2.4. Current topics from breast cancer care research: parallel workshops
The four workshops were dedicated to themes relevant for the development and 
implementation phases of ECIBC objectives, and particularly of the European 
QA scheme.
The results of the parallel sessions were presented by a rapporteur per session in 
the morning of 11th December.
3.2.4.1. Parallel workshop 1: Continuity of care for breast cancer: 
what is it about and how can it be measured?
Charles Shaw (chair), Anke Bramesfeld as JRC coordinator
For a successful treatment of breast cancer patients, both a multi-disciplinary ap-
proach and a structured network of various services are needed. Thereby assuring 
continuity of care between the various services (potentially governed by different 
entities) is a crucial issue for the quality of care. Continuity of care implies conti-
nuity in terms of disease management, transmission of patient’s data/information, 
and relation of patient to service providers. This parallel session explored (i) which 
are the sensitive issues in assuring continuity in breast cancer care, and (ii) how 
quality of care can be assessed with respect to its continuity. It aimed at developing 
examples, options and ideas for assessing continuity of care in a reliable and valid 
way that allows for comparison of services. Based on the two presentations report-
ed below, open discussion with participants looked at how the examples presented 
could be applied to other health systems and what assessment of continuity of care 
should look like, if applied on a European level. Both presentations report exam-
ples of how to measure continuity of care as a dimension of quality of care:
• Integrated Care–what is important and how do we measure it? (Jenny King, Picker 
Institute) 
 This presentation looked at what is important from a user perspective in per-
son-centred coordinated care including the things users believe should always 
happen for care to be coordinated. It looks then at a project aimed to produce 
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a robust user-reported measure that can capture the experience of older people 
with chronic conditions receiving health and/or social care services from dif-
ferent providers. The tool, under development by the International Foundation 
for Integrated Care, National Voices, the Nuffield Trust, the Picker Institute, 
and The King’s Fund in England looks to assess coherence, coordination and 
quality of care. 
• Continuity of care (Simone Wesselmann, German Cancer Society)
 Continuity of care, from the patients’ perspective, is a core element of good 
care. It comprises three major points: (1) one care provider for the patient with 
breast cancer who is a stable contact person through the complete care pathway 
(2) communication between care providers and (3) cooperation between care 
providers. The European QA scheme follows a patient-centred approach and 
therefore requirements must be defined which reflect the three aspects and 
focus on multidisciplinary, inter-professional communication and cooperation 
of care providers in a certified network along the treatment pathway of breast 
cancer patients. Additionally, the requirements must be uniquely defined and 
(if applicable) measurable in order to be used by care providers for quality as-
surance and improvement.
The discussion following these two presentations highlighted the contribution of 
the different professions involved in breast cancer care to the realisation of coordi-
nated and continuous care. The more complex breast cancer centres/services are, 
the greater the need of a secure, interoperable and sustainable system for trans-
mission of data; the same applies to complex decentralised/networked structures.
3.2.4.2. Parallel workshop 2: Communication in person-centred services
Luzia Travado (chair), Liisa Pylkkanen as JRC coordinator
All information concerning breast cancer, should be delivered to both patients 
and healthy women (e.g. in screening) in an honest, clear and easily understanda-
ble way, and if applicable, visual information and decision-aids may be used. All 
patients should be given choices and enough time to decide on treatment options, 
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Picture 3: Panel of parallel workshop 1.
 
 
participation in trials and tissue donation. Communication training is an essen-
tial tool for healthcare professionals to be able to correctly interact with patients. 
Furthermore, the continuity of communication needs to be ensured throughout 
the entire patient journey–keeping the person in the centre. This parallel session 
focussed on three main topics: (i) which are the sensitive issues in the continu-
ity of person-centred communication in breast cancer care (e.g. problems), (ii) 
how the continuity of communication can be improved (e.g. tools), and (iii) how 
the continuity and person-centredness of communication can be measured (e.g. 
indicators). In particular, examples and possibilities for assessing person-centred 
communication in breast cancer services in order to facilitate development of 
recommendations and enable comparison of the quality of breast cancer services 
were presented. The three presentations focussed on how the continuity and pa-
tient-centredness in communication can be improved and measured.
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• Psychosocial support and communication needs of breast cancer patients (Luzia Travado, 
Champalimaud Clinical Centre, Lisboa)
 Good and effective communication is considered a key component of good 
medical practice, and a core competence that can be trained. Therefore, it is 
necessary to systematically train healthcare providers in breast cancer care in 
communication skills. Communication skills training (CST) should be there-
fore offered in undergraduate and postgraduate curricula for physicians, nurses, 
and other allied healthcare professionals in cancer care and in continued pro-
fessional development programmes in psychosocial oncology in all cancer set-
tings. 
 However, much remains to be done, for instance, in establishing requirements 
for clinical practice (and for the European QA scheme) related to communication.
• How continuous communication can be ensured throughout the patient journey (Yvonne 
Wengström, Karolinska Institute and University Hospital, Stockholm)
 Professor Yvonne Wengström discussed the continuity and assessment of per-
son-centred communication.
 She highlighted that person-centred care is responsive to consumer needs, val-
ues and preferences, is integrated and coordinated, relieves physical discomfort, 
provides emotional support, allows involvement of significant others and sup-
ports the provision of information, communication and education to enable 
individuals to understand and make informed decisions about their care.
 She also emphasized that the health care professionals need to communicate 
in a manner that patients could understand and provide accurate information 
according to patients’ preferred information level.
 The enabler of person-centred communication is patient-physician communi-
cation. The key dimensions in person-centred communication are information, 
involvement in care and empowerment–including physical and emotional 
support.
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• Patients’ perspective (Kathi Apostolidis, European Cancer Patient Coalition)
 Kathi Apostolidis presented how communication in cancer care too often is 
only disease-centred and not patient-centred. Thereby important issues related 
to the patients’ wellbeing as well as those related to the integration of cancer 
care into the patients’ daily life are not addressed.
The following discussion highlighted the need of a more holistic view of patients 
as persons in order to be able to meet communication needs. When talking to 
patients, more than just the information on disease and treatment needs to be 
delivered.
3.2.4.3. Parallel workshop 3: Key outcomes for studies on breast cancer screening
Roberto D’Amico (chair), Jesús López Alcalde as JRC coordinator
The third parallel session discussed a core set of desirable and undesirable out-
comes to be assessed in breast cancer screening studies in order to facilitate an 
informed decision making. Two presentations prepared the discussion on this key 
topic:
• Contribution 1 (Mireille Broeders, Radboud University Medical Centre)
 Continuous monitoring and evaluation of a screening programme is neces-
sary to ensure that it is as effective as expected. Screening outcomes, both de-
sirable and undesirable, become available throughout the screening process 
and afterwards. In general, a distinction can be made between evaluating the 
performance of the screening programme and its impact on health indicators, 
such as mortality. Performance indicators reflect the provision and quality of 
the activities constituting the screening process without directly reflecting the 
reduction in mortality. Evaluating the long-term benefits and harms of screen-
ing for breast cancer takes many years and requires the application of complex 
epidemiological and statistical methodologies. Ascertainment of impact of the 
programme further demands that follow-up of screened and non-screened co-
horts continues over extended periods of time and that adequate links exist 
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between programme data and other relevant data sources. A frequently used 
but challenging alternative is to identify and monitor early surrogate measures, 
such as the rate of advanced cancers, that can possibly predict outcome.
• Contribution 2 (Bettina Borisch, University of Geneva)
 The study and evaluation of outcomes for breast cancer screening (programmes) 
is important for the individual as well as for the public health institutions that 
run screening programmes. EU member countries and their respective health 
care systems may value outcomes differently and the single citizen has again 
another demand as to the quality and outcomes of screening. The citizens as 
well as the ‘national’ questions that may need further outcome studies were 
presented.
The discussion that followed highlighted that it is not just a question of choosing 
the right outcome parameters for screening but more so it is important how the 
information provided by outcome parameters on screening is forwarded in an 
understandable way to citizens.
3.2.4.4. Parallel workshop 4: Volume-outcome relation in breast cancer care
Ina Kopp (chair), Silvia Deandrea as JRC coordinator
In spite of the consistent results shown for several other diseases (i.e. AIDS, ab-
dominal aortic aneurysm coronary angioplasty, myocardial infarction, knee ar-
throplasty, coronary artery bypass, etc.), the extent of the association between the 
volume of activity and the outcomes for breast cancer care is not always straight-
forward. This is due to the fact that results depend, among other factors, on the 
definition of caseload (whole hospital, centre, surgeon, etc.), the outcome cho-
sen (mortality, proxies, etc.), and the set threshold. Selection bias and a different 
case-mix also deserve careful statistical adjustment. The objectives of this session 
were (i) to explore the existing evidence on the association between caseload and 
outcome for breast cancer, and (ii) to discuss the most appropriate and feasible 
outcomes to be measured for this purpose.
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Contributions from experts from different countries may stimulate a discussion 
on how healthcare policies introducing (or not) thresholds in the number of cases 
treated affected the organisation of cancer care and the access to the services. 
Two presentations, both reporting examples of the assessment of the impact on 
volumes on outcomes in (breast) cancer care, were offered as a starting point for 
discussion.
• The Italian National Outcomes Programme (PNE) (Marina Davoli, Outcome Eval-
uation Programme–National Agency for Health Services)
 Hospital or physician volume represents a measurable variable with a relevant 
impact on effectiveness of health care. Since 2009, the National Outcomes Pro-
gramme (PNE) evaluates outcomes of care of the Italian hospitals; nowadays it 
represents an official tool to assess the National Health System (NHS).
 There is clear evidence from the scientific literature of an association between 
volume of breast cancer surgery, 30 days intra hospital mortality, five years 
survival and rate of conservative surgery. Although the systematic review of 
the literature does not permit to identify predefined volume thresholds, the 
EUSOMA guidelines identify a minimum threshold of 150 for a breast unit and 
50 for single surgeon.
 In Italy in 2014 there are 467 hospitals performing more than 10 breast cancer 
surgeries, among these only 123 (26%) perform more than 150 surgeries corre-
sponding to 70% of operated women. The biggest hospitals often have more 
than one ward in which surgery is subdivided; the proportion of women having 
surgery in high volume wards (more than 135) is 62% in 2014, as compared with 
54% in 2010; we also observed a great geographical variability.
 In June 2014 the Ministry has approved a national guideline for the organiza-
tion of the breast units and some regions are reorganizing the breast cancer 
network of hospitals to comply with different standards including the volume 
of care. However, the available data from PNE show that it is still very high the 
proportion of women having breast cancer surgery in proper sites.
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• Retrospective analysis on case numbers and process quality in breast surgery in Germany 
(Günter Heller, Federal Institute for Quality Assurance and Transparency in 
Healthcare (IQTIG))
 Background: Numerous studies from around the world have shown a pos-
itive association between case numbers and the quality of medical care. The 
evidence to date suggests that conformity to guidelines for the treatment of 
patients with breast cancer is better in German hospitals that have higher case 
numbers.
 Methods: We used data obtained by an external programme for quality as-
surance in inpatient care (externe stationäre Qualitätssicherung, esQS) for the years 
2013 and 2014 to investigate seven process indicators in the area of breast surgery, 
including histologic confirmation of the diagnosis before definitive treatment, 
axillary dissection as recommended by the guidelines, and an appropriate tem-
poral interval between diagnosis and operation. Case numbers were categorised 
with the aid of various threshold values. Moreover, subgroup analyses were 
carried out for patients under age 65, patients in good general health, patients 
without lymph-node involvement, and patients with a tumour size pT0 or pT1 
or an overall tumour size less than 5 cm.
 Results: Data on 153475 patients from 939 hospitals were analysed. Six of seven 
indicators had values that were better overall, to a statistically significant extent, 
in hospitals with higher case numbers. Although this relationship was not con-
sistently seen, the worst results were generally found in the category with the 
lowest case numbers. Similar, though less striking, results were obtained in the 
subgroup analyses. An exception to the general finding was that, in hospitals 
with higher case numbers, the interval between diagnosis and operation was 
more often longer than three weeks.
 Conclusion: Guideline adherence is higher in hospitals that treat more cases. 
The present study does not address the question whether this, in turn, affects 
morbidity or mortality. To improve process quality in peripheral hospitals, the 
quality assurance programme should be continued.
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The chair and Silvia Deandrea from the JRC explored and discussed with the par-
ticipants the methodology and clinical issues arising from the presentations and if 
the European QA scheme on breast cancer should or should not take into account 
the volume of activity of the centres seeking certification.
3.3. Day 3: The way forward
3.3.1. Keynote
• Dealing with evidence from qualitative research in guideline development (Özge 
Tunçalp, Department of Reproductive Health and Research, WHO)
 There is growing recognition that guidelines questions sometimes fail to reflect 
the priorities of key stakeholders and that issues related to the acceptability 
and feasibility of the recommended interventions are not necessarily addressed 
through effectiveness reviews. Qualitative syntheses are increasingly conducted, 
but methods to assess how much confidence to place in synthesis findings, 
which is an essential consideration for guideline development, are poorly de-
veloped. The Confidence in the Evidence from Reviews of Qualitative research 
(CERQual) approach provides a transparent approach to assess how much 
confidence to place in findings from a qualitative evidence synthesis. Like the 
GRADE approach (Grading of Recommendations Assessment, Development 
and Evaluation), currently used for effectiveness evidence, this approach facil-
itates the use of qualitative evidence to inform decisions and shape policies. 
Department of Reproductive Health and Research of the World Health Organ-
ization, as part of the GRADE-CERQual Project Group, has been developing 
guidelines conducting and incorporating evidence from qualitative syntheses.
3.3.2. Report from the parallel workshops
Four rapporteurs shortly summarised to the audience the main points discussed 
during the parallel workshops and as reported in this report in the respective 3.2.4. 
paragraphs. The rapporteurs where: Luigi Cataliotti for the Parallel workshop 1: 
Continuity of care for breast cancer: what is it about and how can it be measured?, Luzia 
Travado for the Parallel workshop 2: Communication in person-centred services, Holger 
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Schünemann for the Parallel workshop 3: Key outcomes for studies on breast cancer 
screening, and Robert Mansel for the Parallel workshop 4: Volume-outcome relation 
in breast cancer care.
1. Continuity of care for breast cancer: what is it about and how can it be measured?
Continuity of care relates to person centred coordinated care and should be un-
derstood as one of the key features of quality of care. Especially in the complex 
treatment processes of long term care, that not only require medical but also psy-
chosocial interventions, continuity of care is of key relevance. Continuity of care 
relates to the continuity of information across treatment processes and facilities, 
continuity of the management of treatment and continuity of relationship, nota-
bly the relationship between healthcare professionals and patients.
The assessment of continuity of care needs the patient perspective. Continuity of 
care becomes particularly relevant when transitions in care are planned, such as 
discharge to outpatient care, but also if transferred to other services, when outpa-
tient care and care in the home environment is set up and in unplanned situations 
such as emergency admissions to hospital. The quality of continuity of care from 
the patient’s perspective, which should be regarded as the ultimate judgement of 
its realisation, needs to be assessed through patient questionnaires.
From the facilities’ perspective, continuity of care can be seen in the successful 
integration of different health and social care providers. Even if care is provided 
by different facilities and institutions, requesting them to present their quality of 
services together as unique/networked provider is already a first step to scrutinize 
their processes of continuity of management and information. Further quality in-
dicators related to continuity of care can focus on specific processes and structures 
that are essential for implementing continuity of care, such as case discussions or 
pre- and post-treatment multidisciplinary conferences.
2. Communication in person-centred services
The way by which healthcare professionals communicate with patients impacts 
on the quality of the provider-patient relationship, patient’s adjustment to dis-
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ease and treatment, clinical outcomes, and the  patients’ satisfaction, but also the 
clinician’s satisfaction and well-being and the healthcare economy. Healthcare 
professionals need to be trained in effective and patient centred communication. 
Such training can be integrated in undergraduate and postgraduate curricula for 
physicians, nurses and other allied healthcare professionals in cancer care. It also 
can be part of continued professional development programmes in psychosocial 
oncology in all cancer settings.
Patient centred communication differs from disease centred communication by 
taking into account patients’ preferences and state of mind. Today’s patients differ 
from those 15 years ago as they have more access to information, notably through 
the internet but also a desire for refined honest and clear information relating 
not only to disease and symptoms, but also to treatment alternatives, effects of 
treatment, risks, impact on quality of life and self-help opportunities. Benefits and 
harms of all interventions should be communicated honestly, clearly and effec-
tively, patients’ preferences and values need to be considered in communication 
and decision making. Finally citizens/patients should be given enough time to 
make an informed decision.
Indicators related to communication can be those measuring structure, such as 
the availability of courses for communication. Outcome indicators would be pa-
tient reported outcomes (PROMS), thus requiring patient questionnaires.
3. Key outcomes for studies on breast cancer screening
The effectiveness of screening is defined considering the balance between bene-
fits, such as reducing mortality and morbidity, and harms, such as those related 
to overdiagnosis and overtreatment. The evidence for these originates from ran-
domised controlled trials (RCT) and observational studies. When estimating the 
balance of benefits and harms of screening interventions using available studies, 
these need to be comparable in terms of considering the same screening setting, 
and the same screening scenario. Benefits and harms need to be measured using 
the same outcome. In addition, the cultural context of screening needs to be 
considered. When choosing the endpoints/outcomes for scrutinizing screening, 
they should represent what is important from a patient’s perspective, not what is 
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reported by the single studies. Ideal measures of benefit and harms in screening 
include quality adjusted life years (QALY) or disability adjusted life years (DALY). 
There is no consensus on how outcomes should be defined. A systematic way to 
do it would be using Delphi methodology, thus letting multidisciplinary panels 
assess and rate all possible outcomes for their importance and by this method rank 
them. The outcomes defined through this process can then be subject to PICOs. 
A recommendation for screening should be based on a precise definition of the 
question/problem, its benefits and harms, and the quality of the evidence for 
benefits and harms. However, it must also consider underlying values, available 
resources, equity issues, acceptability and feasibility.
4. Volume-outcome relation in breast cancer care
The discussion touched several hot topics related to the question of volume–out-
come relation in breast-cancer care. Can a volume-outcome relation be consid-
ered for cancer care, which is a rather diverse process, and for breast cancer care 
in particular? Breast cancer care includes a multitude of treatment processes, in-
cluding diagnostics, surgery, chemo- and radiotherapy, rehabilitation etc. To what 
extent does volume-outcome relation apply to all these processes? In particular, 
the volume-outcome relation for diagnostics needs to be distinguished from that 
for treatment.
When considering the impact of volume on outcomes, meaningful outcomes 
should be considered, taking into account citizen/patient values. Possible out-
comes include mortality, relapse, and quality of life. However, in particular rele-
vant outcomes, such as relapse or survival take quite some time to evolve and are 
influenced by multiple factors beyond the treatment quality. Bias and confound-
ing variables need to be taken into account, and outcomes should be risk-adjusted 
as well as possible.
Further in the discussion on volume-outcome relation, the unit needs to be de-
fined to which the volume-outcome relation refers to: a hospital, a hospital unit, a 
ward, a physician’s workload. Finally, before recommending specific volume out-
comes, their practical implementation and policy context needs to be considered.
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Picture 4: Presentation of the results the parallel workshop 3.
3.3.3. Last minute presentations
There were three last minute presentations:
• Ana Molina, FISABIO, Spain reported about a study on equity of access to 
breast cancer screening programmes in 27 European countries. Most of the 
countries periodically monitor participation to screening according to diverse 
socioeconomic variables; 17 countries report about interventions to tackle so-
cial inequalities in participation, mostly by a general approach. She concluded 
that more focused interventions are needed to overcome social inequalities in 
participation in breast cancer screening programmes.
• Elizabeth Benns, Independent Cancer Patients’ Voice, UK reported on her ex-
perience as a patient representative participating in the auditor team of breast 
cancer care facilities.
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• Ina Kopp, Guidelines International Network, Institute for Medical Knowledge 
Management, Germany provided feedback on ECIBC activities that were pre-
sented in the plenary from an ‘outsider’ and methodology expert point of view. 
She called on the ECIBC to be very transparent, for instance by publishing on 
the web hub not only the documents, the objectives, and the working groups’ 
members’ profiles, but the methodological approach as well. She judged ISO 
accreditation in the field of medical treatment as risky, however less problem-
atic in the field of testing/examination processes. All in all she valued the open 
discussion occurring in the ECIBC Plenaries as a good way to ensure that in-
puts from stakeholders and experts to optimise ECIBC development and im-
plementation chances are received and understood.
3.3.4. Closing words
During the Plenary, GDG and QASDG meetings took place and the GDG co-
chair and QASDG chair reported to the audience the main points agreed during 
those short meetings.
Chris de Wolf (GDG co-chair) reported that the GDG agreed on how to proceed 
with the six chapters of the guidelines (1. Screening, 2. Diagnosis, 3. Communica-
tion, 4. Training of professionals, 5. Interventions to reduce inequalities, and 6. 
Monitoring and evaluation) in order to set the PICO (Population, Intervention, 
Comparison, Outcomes) questions that will be covered by the European Guide-
lines for Breast Cancer Screening and Mammography applying the GRADE method. 
He also explained that these new guidelines will not be focussed on quality assur-
ance as this aspect will be addressed by the European QA scheme and their short 
name was agreed to be European Breast Guidelines. He finally announced that dur-
ing the GDG meetings, great progress in the preparation of the Guidelines scope 
to be submitted to the call for feedback was obtained (the call was in fact launched 
the 18/12/2015).
Robert Mansel (QASDG chair) described to the audience how the work of the 
QASDG was agreed to be organised, by subgroups (Testing-Imaging, Pathology, 
Medical Physics, Molecular/Genetic Testing, Competence, Organisation, Scope 
and Modules, Certification Processes, Indicators, Research) and task forces in col-
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laboration with the GDG (screening and diagnosis [GDG] with testing activities, 
such as medical imaging, clinical pathology, medical physics, molecular/genetic 
testing [QASDG], training [GDG] with competence [QASDG], monitoring 
[GDG] with indicators [QASDG], glossary [GDG] with quality concepts and 
key-words [QASDG]). He reported that the organisation of the sub-group activ-
ities was prioritised as functional to the development of the QA scheme scope to 
be submitted to the call for feed-back, which was planned to be launched at the 
beginning of 2016 (the call was in fact launched the 17/02/2016).
Donata Lerda (JRC) closed the conference inviting participants to visit the newly 
launched ECIBC web hub and to join the ECIBC Plenary 2016 (24th and 25th No-
vember 2016, again in the Lake Maggiore district).
Central findings of the plenary meetings refer to:
• The importance of keeping the transparent and inclusive character of the ECIBC. 
The web hub is the key channel in this respect. It aims to serve as an interface 
between the ECIBC and citizens and stakeholders. With the launch of the web 
hub, the first important milestone of the ECIBC has been reached.
• The need to publically share the methodologies applied and the expected time-
line to better prepare the acceptance and implementation of the European QA 
scheme and of the European Breast Guidelines. All along its development phase, 
information and documents on the ECIBC will be made publicly available on 
the web hub.
• The importance of combining a rigorous and methodological sound approach 
with the flexibility required to adapt both the scheme and the guidelines to the 
different healthcare systems in Europe, respecting their diversity.
• The ECIBC welcomes contributions and inputs. Besides the annual Plenaries, 
calls for feedback on the scope of the European QA scheme and of the European 
Breast Guidelines are organised for the end of 2015-beginning of 2016; the final 
versions, expected for 2018, will be as well submitted to a call for feedback. These 
calls represent a key moment for the project to receive inputs from stakeholders 
and the public, ensuring that most of the possible obstacles for implementation 
can be ironed down before the roll-out phase.
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The second ECIBC plenary set out to inform stakeholders on the current state 
of the ECIBC projects and to engage them in the discussion on burning topics 
connected to the quality of care for breast cancer, hence relevant for the ECIBC. 
The plenary was a wide success, as the general positive feedback from participants 
suggests. In detail the plenary succeeded in:
• Explaining the methodology, scope and current state of development of both 
the European QA scheme and the European Breast Guidelines. Many of the free-text 
comments of the evaluation forms referred to the information on ECIBC as 
having been very meaningful to participants.
• Seeking feedback from stakeholders on the ECIBC, in particularly on the Euro-
pean QA Scheme and the European Breast Guidelines. Thereby, stakeholders made 
explicit that the methodology used to develop both the European QA Scheme 
and the European Breast Guidelines needs to be better detailed to the public, 
possibly directly on the homepage of the ECIBC web hub, at least during the 
ECIBC development phase.
• Communicating the framework under which the European QA Scheme will work 
together with countries and National Accreditation Bodies (NAB) to ensure that 
what is being developed will be feasible and that countries’ uptake will induce 
a significant impact on citizens, and women in particular. This was achieved via 
presentations on the ECIBC, countries and NABs posters and presentations 
aimed at ensuring a transparent communication about the accreditation frame-
work applied for the European QA Scheme.
• Receiving input for the ECIBC on subjects highly relevant to quality of care 
and measurement of quality of care. The parallel workshops on continuity of 
care, on communication in person-centred services, on key outcomes for stud-
ies on breast cancer screening and on the volume-outcome relation in breast 
cancer care were key for collecting meaningful ideas and inputs.
• Receiving input for key themes for ECIBC: the keynote lectures (one on the 
concept of patient centred care and one about using qualitative research for 
guideline development) certainly provided important indications on the way 
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forward considering two important aspects, the first more relevant for the con-
tent, the second for the methodology, but closely interlinked. They helped in 
clarifying that the ECIBC needs to focus on patient experience rather than 
patient satisfaction and that for patient centred guidelines, qualitative research 
is essential.
On the basis of the experience from the ECIBC Plenary 2015, the ECIBC Plenary 
2016 will again report on the state and progress of the ECIBC projects during 2016.
Furthermore, the ECIBC Plenary 2016 will again ask countries and National 
Accreditation Bodies to present themselves, interact with each other, engage in 
commenting and contributing to the European QA scheme, and contextualise their 
preparedness to the piloting and running of the European QA scheme. This means, 
that the JRC will do its best to increasingly engage these key ‘implementing’ ac-
tors, also by having more countries’ and NABs’ presentations.
As the keynotes were highly appreciated and so stimulating, the Plenary 2016 will 
also invite keynote speakers to provide new and different insights, potentially 
more focussed on the implementation needs. The ECIBC 2016 will continue to 
provide a platform for networking at the interface between research and policy to 
improve care for women confronted with breast cancer.
Finally, as the 2015 ECIBC plenary succeeded in grasping the interest of the Euro-
pean Parliament, through video messages by the Vice-President of the European 
Parliament and of the President of the Member of Parliament’s Against Cancer 
group, the 2016 ECIBC plenary aims to engage a greater number of policy repre-
sentatives.
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Picture 5: Participants to the 2015 ECIBC Plenary.
Figure 1: Overall evaluation of ECIBC plenary, n= 46.
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46 participants of the ECIBC plenary filled out the feedback questionnaire (cor-
responding to approximately 50% participation). In general responses were over-
whelmingly positive. The content and the quality of the presentations met or even 
exceeded the expectations of more than 90% of the respondents for the plenary 
sessions at Day 1 (Current state of ECIBC-projects) and Day 2 (Current topics 
in breast cancer care plenary). At Day 3 (The way forward), after two very intense 
days, still 86% found that their expectations were met or exceeded.
Most of the comments and feedback were related to discussion time not being 
felt sufficient (by about 20% of respondents at Days 1 and 2 and by 15% at Day 3). 
In line with this, 15% of respondents felt that time for bilateral discussion and 
networking was not enough, while general communication with participants was 
judged as good. While this is an encouraging message, showing the great interest 
risen by the topic and favoured by the event’s design, it is certainly a message to 
be taken home for carefully balancing presentations with discussion time at the 
next ECIBC Plenary. The location (Hotel Dino in Baveno) exceeded expectations 
of most of the participants, therefore the JRC will pay the due attention also to 
the logistical aspects.
In an open section of the questionnaire, respondents listed what they felt had 
been most meaningful to them at the conference. Most often respondents listed 
the country profiles, both as presentations and as posters, as having been most 
meaningful to them. These country profiles presented the actual status of breast 
cancer care and its quality assurance in the countries (and are key for understand-
ing which are the implementation needs and potentials for the ECIBC). Similarly, 
National Accreditation Bodies’ posters on their activities related to breast cancer 
care were appreciated. The updating on the ECIBC projects, namely reporting on 
the development of the European Breast Guidelines as well as the activities related 
to European QA scheme were also felt to be most meaningful to many. Both 
keynotes, the one on patient centredness and the one on how to use qualitative 
research as evidence for guideline development, received a positive feedback.
5. Evaluation of the event
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Picture 1: Participants to the 2015 ECIBC Plenary.
Picture 2: Audience to the ‘Current state of the ECIBC project’ session.
Picture 3: Panel of Parallel workshop 1.
Picture 4: Presentation of the results the Parallel workshop 3.
Picture 5: Participants to the 2015 ECIBC Plenary.
Figure 1: Overall evaluation of ECIBC plenary, n =  46.
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Tit Albreht, M.D. (1961), Slovenian, Ph.D. in Health Services Research at 
the University of Amsterdam, Head of the Centre for Health Care, Na-
tional Institute of Public Health of Slovenia, Senior Researcher in the field 
of health services research, health policy and health systems, member of 
the Scientific Committee of EUPHA, member of the Slovenian Preven-
tive Medicine Society, member of the Health Council of the Ministry of 
Health of Slovenia. He is an Associate Professor of Public Health at the 
Department of Public Health of the Medical Faculty in Ljubljana. He acts 
as a reviewer of several scientific journals and of projects submitted for fi-
nancing to the European Commission. He is currently coordinator of the 
Joint Action Cancer Control (CanCon), dedicated to the development of 
health policy support and advice to cancer control policies at the level of 
the EU and of the Member States.
Dr Kathi Apostolidis. Kathi is the Vice President of ECPC-European 
Cancer Patient Coalition and a Public Affairs Consultant with extensive 
experience in regulatory affairs, marketing and communications. She rep-
resents ECPC at the EMA’s Patients and Consumers Working Group, 
she is member of the European Commission Expert Group on Cancer 
Control and of the Expert Group EIBC/QASDG on the Commission 
Initiative on Breast Cancer, participates as ECPC representative in Work 
Packages of the EU Joint Action on Cancer Control. She is a member of 
the Cancer Patients Working Group of ESMO, of the Steering Commit-
tee of HTAi’s Patients and Citizens Involvement Group. At the national 
level, she is the Chair of the Intergroup Committee for Cancer Patient 
Rights Advocacy/Greece (DEDIDIKA), she serves as a Deputy Board 
Member at KEFI-Association of Cancer Patients, Volunteers and Physi-
cians/Greece, and is also member of other Greek and international cancer 
patient associations. As a twice breast cancer survivor, she was involved 
in breast cancer and cancer patient rights advocacy since 1995. She has a 
broad interest in cancer care policy and many aspects of front line can-
cer care, survivorship, cancer research and economics, health technology 
assessment, digital technology in cancer care. Graduate of the University 
of Athens, Philosophy Dept. and Political & Economic Sciences and of 
McGill University, Canada in Business Administration. She is a member 
of the editorial board of the Journal of Compassionate Health Care.
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Prof. Bettina Borisch, Professor of Public Health, Institute of Global 
Health, University of Geneva. Director of the World Federation of Public 
Health Associations, headquartered in Geneva. Dr Borisch is an MD and 
a Histopathologist, MPH and Fellow of the Royal College of Pathology 
(UK). Her scientific research work delves into neoplastic lesions of the 
immune system and breast cancer. Her interests also include communi-
ty-based oncology, health communication and global health. She studied 
medicine and history at the Universities of Kiel (Germany) and Lausanne 
(Switzerland). She is appointed professor and head of the Institute of Clin-
ical Pathology, University of Geneva in 1995. She becomes the president of 
the Swiss Cancer League’s program against breast cancer. She completes 
an MPH in 2005 and orientates her activities to Public Health and Global 
Health. She joins the Institute of Social and Preventive Medicine in 2005 
(from 2015 on: Institute of Global Health). She is Editor in Chief of Patho-
biology and the Co-Editor of Journal of Public Health Policy. In addition 
to her academic work she acts as the Director and Head of the World 
Federation of Public Health Associations and holds positions at several 
Committees of Public Health oriented institutions. She was president of 
Europa Donna–The European Breast Cancer Forum and Founding Pres-
ident of the Swiss Forum of Europa Donna. She teaches at the University 
of Geneva, the Swiss School of Public Health and she also teaches patient 
support groups. She is (co)author of over 120 scientific papers.
Dr Mireille Broeders is a cancer screening epidemiologist with an academic 
degree in bio-medical health sciences. She is an Associate Professor at the 
Dept. for Health Evidence, Radboud University Medical Centre, in Nij-
megen, the Netherlands. Her research focuses on establishing the impact of 
cancer screening programmes, in particular screening for breast cancer, and 
the potential value of moving to risk-based screening regimens. She has a 
special interest in observational research designs that can be used in this field 
of research. As a long-standing member of the National Evaluation Team 
for Breast Cancer Screening, she is also involved with the evaluation of the 
long-term benefit and harms of the Dutch nation-wide breast screening pro-
gramme. She further works as scientific supervisor at the Dutch Reference 
Centre for Screening in Nijmegen. This has broadened her research interests 
to include e.g. the implementation and evaluation of technological develop-
ments in the breast screening programme, pain experience during breast com-
pression and test sets for radiologists. All research projects at the Centre aim 
at the safeguard and constant improvement of the quality of the breast cancer 
screening programme. At a European level, she contributed, as editor and au-
thor, to the European Guidelines for Quality Assurance for Breast Screening 
and Diagnosis. She has been co-leading the EUROSCREEN working group, 
a European research effort to summarise breast cancer screening service 
screening outcomes, published as supplement to the Journal of Medical Screen-
ing (2012). She has co-authored over 100 papers in peer-reviewed journals.
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Dr. Miriam Dalmas I am a medical professional specialising in Public 
Health Medicine. Since 2009, I have been engaged as a medical consultant 
in Public Health Medicine. My main role is in the coordination of poli-
cy development and in providing general support to the Chief Medical 
Officer (CMO). I occupied the post of Director for Policy Development, 
EU and International Affairs for the Ministry for Health from 2007-2011. 
For the past six years my work has focussed on the national cancer policy 
and I was the main author of the National Cancer Plan 2011-2015. I have 
also led the creation of the National Health Systems Strategy 2014-2020 
that was launched in 2014. Presently, I am representing Malta as an asso-
ciate partner in the Joint Action on Comprehensive Cancer Control (JA 
CANCON) and on the Board of Member States on the European Refer-
ence Networks. Recently, I have been tasked with the coordination of a 
new National Cancer Plan 2016-2020. In 2005, I graduated as a Master in 
Business Administration from the University of Malta. Since 2010, I am 
a doctoral candidate with the Faculty of Economics, Management and 
Accounting at the University of Malta in the field of Management and 
specifically on the subject of Organisational Learning.
Marina Davoli. Scientific Director, Italian National Outcome Program 
Department of Epidemiology Lazio Region, Roma, Italy. Medical Degree 
in 1985 at the University of Rome ‘La Sapienza’. Master of Science (MSc) 
in Epidemiology–London School of Hygiene and Tropical Medicine in 
1991. Head of the Department of Epidemiology, Regional Health Service, 
Lazio Region, Operational Centre of the National Outcome Program. 
Member of the Regional Drug Formulary of the Lazio Region. Member of 
the Scientific Committee of the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) in Lisbon. Coordinating Editor of the 
Cochrane Drugs and Alcohol Group. Member of the GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) Work-
ing Group. Main activities: systematic reviews of the scientific literature 
on the effectiveness of health care interventions; epidemiological studies 
on the health status of the population; comparative effectiveness research 
on drugs and other health care interventions; comparative analysis of 
health care outcomes across hospitals and geographical areas for the Na-
tional Outcome Evaluation Programme and the Lazio Regional Outcome 
Evaluation Programme; coordination of the work package of the EU Pro-
ject DECIDE on strategies for the dissemination of evidence to policy 
makers. Author of more than 100 scientific publications on peer reviewed 
journals, H index 21.
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Henricus J de Koning. Born in the Netherlands, Professor Henricus (Har-
ry) J de Koning worked as a Researcher and an Assistant Professor in the 
Department of Public Health of the Erasmus University in Rotterdam 
from 1987 to 1999. He became an Associate professor in 1999 and in 2008 
he was appointed Professor of Public Health & Screening Evaluation in 
the same department in Rotterdam. He was also Senior Associate Depart-
ment of Health Policy and Management at the Johns Hopkins Bloomberg 
School of Public Health from 2011 to 2012. Since 2011 he has been a Mem-
ber of the Medical Advisory Board of the Royal Netherlands Academy of 
Arts and Sciences (KNAW). His major scientific contributions are in the 
areas of: designing, running and evaluating large-scale multidisciplinary 
population-based randomized controlled screening trials to establish the 
efficacy of screening; evaluating active international screening programs 
and tests to establish effectiveness; guiding public health policies using 
predictions of favourable and unfavourable effects and the cost of screen-
ing, based on micro-simulation modelling of the natural history of dis-
ease, and cost-effectiveness and cost-utility analyses.
Dr Chris de Wolf. I am a medical expert specialised in breast cancer 
screening. I studied medicine in the Netherlands (VU Amsterdam) and 
afterwards I was engaged by the policy development department of the 
Dutch Ministry of Health (1989-1990). On request of the European Com-
mission, I worked on European cancer screening strategies within the Eu-
rope against Cancer program for eight years, where I was charged with 
the development of the European Guidelines for Quality Assurance in 
Breast Cancer Screening and Diagnosis. In 1999 I took a position as Head 
Screening and Early Detection at the International Union against Cancer 
(UICC, Geneva). Between 2004-2014, I had many positions all related 
to breast cancer screening in Switzerland. Currently, I am quality assur-
ance specialist for Swiss cancer screening, medical director of the breast 
screening program in canton Wallis and consultant to the breast screening 
programs in Thurgau and Basel. All these activities I execute through my 
company ADSAN Sarl (Agence pour le développement et évaluation des 
politiques de santé).
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Silvia Deandrea obtained her degree of Medical Doctor and specialisa-
tion in Public Health and Preventive Medicine at University of Pavia, and 
obtained her Biostatistics PhD at University of Milano in 2011. Before 
joining the Joint Research Centre in 2012, she worked in healthcare qual-
ity consultancy for the Joint Commission International, in cancer epide-
miology research at Mario Negri Institute of Pharmacological Research 
(Milano, Italy) and in population-based cancer screening programmes 
organisation and evaluation at Cancer Prevention Unit of Milano Local 
Health Authority. For the breast and colorectal cancer programmes she 
covered the role of quality manager and she coordinated local activities in 
the context of multicentre research projects. Her current research interests 
include quality assessment and standardisation in breast and colorectal 
cancer screening, cancer pain epidemiology and Bayesian methods for 
evidence synthesis. She is author of more than 20 articles published in 
peer-reviewed international journals.
Chris Graham. Chris is the Director of Research and Policy at the Picker 
Institute, a charity with a vision of the highest quality health and social 
care for all, always. Chris has over a decade of experience in working 
on and promoting person centred care and the measurement and use of 
patient experience information. He is currently involved in a number of 
research projects investigating the measurement and improvement of pa-
tient experience. These include a major study investigating the value of 
‘near real-time’ feedback for improving compassion in care, as well as col-
laborating with other charities and academic institutions to develop new 
approaches to measuring integrated care and user experiences along path-
ways. Chris is the chief investigator for the NHS Patient and Staff Sur-
vey Co-ordination Centres, run on behalf of Care Quality Commission 
(CQC) and NHS England respectively, which are sent to over 500000 
people each year. He is an NIHR fellow and an associate member of the 
Health Services Research Unit at University of Oxford. Prior to joining the 
Picker Institute, Chris worked at the CQC and Healthcare Commission, 
where he was responsible for managing national research programmes.
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Guenther Heller, MD PhD. 1996-2002: Institute for Medical Sociology 
and Social Medicine, University of Marburg. 2002-2010: Research Insti-
tute of the Local Sickness Funds (Wissenschaftliches Institut der AOK: 
WIdO). 2010-2015: AQUA–Institute for Applied Quality Improvement 
and Research in Health Care GmbH. Since October 2015: Federal Insti-
tute for Quality Assurance and Transparency in Healthcare (IQTIG). My 
primary research interests lie in the fields of epidemiology and healthcare 
research. I have performed several analyses using large population-based 
datasets addressing volume outcome or volume quality relations, e.g. in 
the fields of perinatology, neonatology and breast surgery.
Solveig Hofvind (1961). Head of the Norwegian Breast Cancer Screening 
Program, professor in radiography at Oslo and Akershus University Col-
lege of Applied Sciences. Hofvind is radiographer by training and did 
her master at the Norwegian school of sport sciences (Physical activity 
and risk of breast cancer). After 13 years work at Akershus University hos-
pital, where she was the pioneer in establishing a breast clinic and the 
Norwegian Breast Cancer Screening Program, she started to work at the 
Cancer Registry of Norway. The Cancer Registry is responsible for the 
administration and quality assurance of the screening program. Hofvind 
started working as information adviser for the breast and cervical cancer 
screening programs in 1998. Four years later she started working on her 
PhD, which she finished in 2005 (The Norwegian Breast Cancer Screening 
Program: Selected process indicators and their utilization in epidemiolog-
ical research). Hofvind was guest professor at the University of Vermont, 
2006-07, and 2010-11 and a substantial network internationally. She has 
about 90 peer-review publications, mainly related to epidemiological as-
pects of breast cancer and mammographic screening.
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Kitti Horváth, MD. I was born in Budapest, Hungary in 1986. I first gradu-
ated from high school in the United States of America (2004) and then in 
Hungary (2006). I started my higher education in 2006 at the Faculty of Med-
icine, University of Szeged, where I had the chance to organize almost all my 
internships abroad experiencing the flow of different health care systems. On 
the field of research I worked at the Institute of Surgical Research of the uni-
versity (new possibilities in sepsis treatment) and also at the centre of Siemens 
Healthcare in Germany (radiological innovations in minimal invasive surgi-
cal interventions). My interest towards health promotion began directly in 
the first year of university, so I joined the Hungarian Medical Students’ Inter-
national Relations Committee (Hu MSIRC) to participate in their prevention 
activities. Following my accession I soon became the national public health 
officer of the committee and after a couple years of national and internation-
al experience I was elected to be the Director of the Standing Committee on 
Public Health of the International Federation of Medical Students’ Associ-
ations (IFMSA) in 2012. This position allowed me to work worldwide with 
medical students as well as with different non-governmental organizations 
for a better future concerning health promotion and care. After graduating 
from medical university I became a resident doctor at the Internal Medicine 
Department of the Hungarian Defence Forces’ Medical Centre. Beyond my 
clinical work I joined the Chief Medical Officer Office of Hungary in 2015 
and started specialising mainly on breast cancer and breast screening.
Michael Hübel, European Commission, DG Health and Food Safety. Pri-
mary and secondary education in Germany and the United States. Studies 
of Political Science (major), Public Law and History in Bonn, Germa-
ny and Canberra, Australia. Work in different German youth and social 
welfare organisations. 1989-1995: German Red Cross, Headquarters, Social 
Welfare Division, initially in the Social Policy Unit, then European Repre-
sentative of the German Red Cross. In the Commission since 1995, initial-
ly in DG V (Employment and Social Affairs). Since 2000: DG Health and 
Consumers, now DG Health and Food Safety, Public Health Directorate. 
Until 2003 in policy analysis and development, working on general health 
policy. From 2003 in the Health Determinants unit, with responsibility for 
social and environmental determinants. Since 2004 Deputy Head of Unit. 
2005-2012: Head of Unit for Health Determinants, with responsibilities for 
nutrition and physical activity, alcohol, chronic diseases and wider deter-
minants of health. Since January 2013: Head of Unit Programme Manage-
ment and Diseases. Responsible for the EU Health Programme and chronic 
diseases, including cancer, and rare diseases, as well as mental health.
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Cary S. Kaufman, MD. Cary Kaufman is an Associate Clinical Professor of 
Surgery at the University of Washington, Fellow of the American College of 
Surgeons and the Medical Director of the Bellingham Regional Breast Centre 
in Washington State. Dr. Kaufman was trained at UCLA and the University 
of Washington and for the last 30 years has practiced as a breast surgeon. His 
professional life has focused on three areas: individual patient care, function-
al research, and physician education. He has lectured on the diagnosis and 
treatment of breast cancer both nationally and internationally. His interest in 
quality assessment of breast care has led him to have served as the Chairman 
of the National Accreditation Program for Breast Centres, the President of 
the National Consortium of Breast Centres, a Board Member of the Amer-
ican Society of Breast Surgeons, a Trustee of the National Consortium of 
Breast Centres and Chair Emeritus of the National Quality Measures for 
Breast Centres. He is a current member of many societies including the Soci-
ety of Surgical Oncology and the American Society of Breast Surgeons. He is 
or has been a journal reviewer for the Annals of Surgical Oncology, the American 
Journal of Clinical Oncology, The Breast Journal, JAMA, and the Journal of Sur-
gical Oncology. He has published over 50 articles on multiple aspects of breast 
care, diagnosis and treatment, including pioneering work on cryoablation for 
breast tumors, assessing the quality of breast care, intraoperative use of breast 
ultrasound, defining the value of preoperative needle biopsy, digital spec-
imen mammography and specimen tomography as well as other subjects.
Jenny King. As Associate Director of Research at the Picker Institute, 
an international charity working across health and social care, Jenny is 
responsible for the organisation’s research work stream. This includes 
managing large scale academic related grant-funded projects and com-
missioned evaluations designed to create new knowledge and influence 
policy and practice in health and social care. Jenny has eight years of 
experience carrying out qualitative and quantitative research exploring pa-
tient centred care, integrated care and staff experience. A current project, 
commissioned by The National Institute for Health Research (NIHR), 
and in collaboration with the University of Oxford, aims to strengthen 
relational care provided in hospitals and to evaluate a real-time feedback 
approach for informing care delivery. The study addresses an urgent need 
for research that evaluates the introduction and impact of real-time feed-
back approaches in the NHS. Jenny joined the Picker Institute in 2008 
after completing an MSc in Forensic Psychology.
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Susan Knox is a two time breast cancer survivor and has been Executive 
Director of Europa Donna since 1999. She is responsible for all on-going 
European advocacy initiatives in the areas of information, education and 
lobbying, including Pan-European advocacy conferences, meetings and 
information sessions at the European Parliament and European Com-
mission, European Breast Cancer Advocacy Training Courses, publica-
tions and websites. In 2008 she launched ED’s first prevention initiative–
BREAST HEALTH DAY, which takes place annually on 15 October (see 
website www.breasthealthday.org). In addition, Susan represents ED on 
numerous other projects: BIG Scientific Committee, MIN-DACT and 
AURORA Committees, European Commission Expert Group on Cancer 
Control, the ECIBC project, and European Breast Cancer Conferences 
(EBCC). She is a speaker on patient advocacy at various international 
conferences and courses and has written widely on the subject. In 2009 she 
was also named advocacy editor of the scientific journal The Breast. Prior 
to joining Europa Donna, Susan held various managerial positions in the 
corporate and non-profit sectors, working for Citibank and a non-profit 
long-term care facility for the aged. Susan holds a B.A. degree from Smith 
College and an M.A. degree from Columbia University.
Donata Lerda. Born in 1962, graduated in Chemistry in 1987. Worked in 
the Public Administration in Italy for more than 20 years and started work-
ing in the EC in 2007. She is expert in quality assurance, accreditation, 
auditing and management of networks; she also has a deep knowledge of 
the European Commission working rules. She coordinates the European 
Commission initiative on Breast Cancer.
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Luciana Neamtiu. Graduated in Mathematics and Physics in 1996, she 
obtained a PhD in Mathematics (Numerical analysis, optimisation and 
computer science applied to medicine) and a Master Degree in Project 
Management. She worked for more than ten years in the area of cancer 
registries and screening databases, and collaborated in setting-up the re-
gional population-based cervical cancer screening programme and cancer 
registry in Romania. She is currently working for the European Commis-
sion’s Initiative on Breast Cancer.
Liisa Pylkkanen, MD, PhD graduated in Medicine in 1986 and obtained 
her PhD in 1992. She is a Specialist in Clinical Oncology (since 1995), 
Health Administration (since 2001) and Palliative Medicine (since 2010). 
She also holds Adjunct Professor position at the University of Turku, 
Finland (since 2001). She has worked for more than 25 years in clinical 
oncology and in different management positions both in academia and 
pharmaceutical industry. Since 2012 she served as Chief Medical Officer 
at the Cancer Society of Finland and currently working as Scientific Pro-
ject Officer in the Healthcare Quality Team at the JRC (since 8/2015). Her 
scientific interest has focused on breast and prostate cancer, bone active 
compounds and patient support.
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Francesco Sardanelli, born in Genoa, Italy (June 14, 1953). Medicine Gradu-
ation (1982) and Post-graduation in Radio-diagnostics (1986), staff radiologist 
(1987-99), and professor at the Post-graduation Course in Radio-diagnostics 
(1992-2000), Genoa University. Director of the Department of Radiology at 
the Research Hospital Policlinico San Donato, Milan, Italy (2001). Associate 
Professor of Radiology at Milan University (2006-2015). Associate Professor/
Full Professor of Radiology, Milan University (2005/2015-). Director of the 
Post-graduation School in Nuclear Medicine (2008-2010) and in Radio-di-
agnostics (2015-), Milan University. Consultant for the Istituto Superiore di 
Sanità (Italian Ministry of Health) and for the national radiological coordi-
nation of three multicentre studies on MRI–including screening of women 
at high genetic-familial risk for breast cancer (1999-2012). Member of the 
Board of Directors of Breast Centres Certification according to EUSOMA 
guidelines. Member of Editorial/Advisory Board of European Radiology, The 
Breast, La Radiologia Medica, American Journal of Roentgenology, Insight Into 
Imaging, Clinical and Translational Imaging, and reviewer for other 48 medical 
journals. Current societal roles: Research Committee, European Society of 
Radiology; Advisory Board, European Institute for Biomedical Imaging Re-
search; Director, Euro pean Network for Assessment of Imaging in Medicine. 
Past-president, Euro pean Society of Breast Imaging. President, College of 
Breast Radiologists by the Italian Society of Medical Radiology. Honorary 
membership, British Society Breast Radiology, Iranian Society of Radiology.
Charles Shaw trained as a doctor (London), manager (Canadian Hospital 
Association), and hospital inspector (Accreditation Canada). He received 
a PhD from the University of Wales on healthcare standards. He worked 
as a manager in the UK NHS, as an academic at University of Bristol, and 
as a policy adviser at the King’s Fund and Department of Health in Lon-
don. Retired from the UK NHS since 2001, he is now visiting professor at 
Macquarie University in Australia, and freelance consultant to ministries 
of health. As former president of the International Society for Quality in 
Healthcare (ISQua), he led a global review of ‘quality and accreditation 
in health care services’ commissioned by WHO Geneva in 2000. He has 
published five European and international surveys of healthcare accredita-
tion programmes, and guidance for new schemes for WHO (HQ, EURO 
and EMRO), for World Bank and for several Ministries of Health. The 
most recent of 150 publications in peer reviewed journals proposes a Euro-
pean initiative to standardise healthcare standards between accreditation, 
certification and regulation. Charles Shaw was leader of the EC research 
project on ‘external peer review techniques’ and a partner in designing 
hospital assessment tools for the EC MARQuIS and DUQuE projects, 
seeking to demonstrate an association between accreditation, certification 
and quality and safety in healthcare.
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Luzia Travado, PhD, MSc, ClinPsych, is clinical health psychologist and 
psychotherapist by the University of Lisbon, specialized in psycho-oncol-
ogy and palliative care, and has doctorate degree in Psychology/Health 
Psychology by the University of Coimbra. She is presently head of Psy-
cho-Oncology at the Clinical Centre of the Champalimaud Foundation, in 
Lisbon, Portugal (2012-). Previously was chief of Clinical Psychology at Cen-
tral Lisbon Hospital Centre-Hospital S. José, where she began her career and 
has pioneered psychosocial programs for chronic disease patients, namely 
breast cancer (1985-2012). She served as adviser for the National Coordinator 
for Oncological Diseases in Portugal (2007-2011). She represented Portugal 
at the European Partnership on Action Against Cancer (2009-2014), and led 
the Psychosocial Oncology Action under this partnership; she presently col-
laborates with the European Cancer Control Joint Action (CANCON). She 
has been involved in European cancer policy being a speaker at various EU 
meetings, summits and conferences concerning cancer control and care in 
Europe, and also international ones related to psycho-oncology. She cur-
rently serves as President of the International Psycho-Oncology Society, and 
was Chair of the IPOS World Congress of Psycho-oncology in Lisbon in 
2014. She serves as Specialty-editor for The Breast and is founder and former 
president of the Viva Mulher Viva Association on breast cancer. She has sev-
eral scientific papers published in Int’l peer-review journals, and book-chap-
ters. She was cover story at Cancer World in the Nov-Dec 2011 issue.
Özge Tunçalp, MD, PhD, is a physician and epidemiologist currently 
based in Geneva as a scientist in the Department of Reproductive Health 
and Research at the World Health Organization. In collaboration with 
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quality of care for maternal and new-born health, including maternal 
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School of Public Health and a postdoctoral fellowship at the Department 
of Obstetrics and Genecology at Yale School of Medicine.
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Yvonne Wengström is an oncology nurse and has worked at the Depart-
ment of Oncology with breast cancer practice since 1989, and holds a PhD 
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Simone Wesselmann. As a trained gynecologist I have been the founding 
member of two certified breast cancer centres in Germany (2003 and 2004). 
The impact of certification on the overall care of patients was strikingly 
convincing. Its success encouraged me to continue my career in the area 
of quality assurance. Subsequently I graduated with a Master’s Degree in 
health care management, and in 2008 I started as head of the certification 
department of the German Cancer Society. Within our certification sys-
tem we have 278 breast cancer centres certified by the German Cancer 
Society and the German Society for Senology in four European Member 
States. These centres are part of a comprehensive oncological certification 
system with in total over 1 100 certified centres for different tumor entities. 
By now the German centres treat 90% of all incident breast cancer cases in 
Germany. I am also a member of the Guideline Group which developed 
the German evidence-based Guideline for Breast Cancer. The guideline is 
the basis for recommendations which must be met during the certification 
procedure. Every year my department publishes the results of over 50000 
breast cancer patients that have been treated in certified centres. In sum, 
my expertise has got breadth and depth, based on many years of experi-
ence in the field of quality assurance. It is part of my daily work to develop 
with other experts guideline based recommendations, quality indicators, 
nationwide working documentation and to implement them successfully.
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